Hugo ten Cate


Prof. Hugo ten Cate graduated in Medicine at the University of Amsterdam in 1987. The title of his PhD thesis was 'Clinical and experimental studies with a low molecular weight heparinoid'. Hugo had his post-doctoral training at the laboratory of Prof. Robert Rosenberg and Dr Kenneth Bauer at the Beth Israel Hospital and Harvard Medical School Boston on mechanisms of inflammation associated coagulation activity (1988-1990). He completed his internal medicine training in 1996 and became a general internist in conjunction with research at Academic Medical Center (laboratory of Experimental Internal medicine, Prof. Pieter Reitsma). He received a Clinical Established Investigator grant from the Dutch Heart Foundation in 1998.

In 2002, Hugo ten Cate was appointed Professor of Clinical Thrombosis and Haemostasis at CARIM. In addition, Prof. ten Cate was appointed adjunct professor at the Center for Thrombosis and Haemostasis (CTH) at Gutenberg University Medical Center, Mainz, Germany in 2017

Since the transfer to CARIM in 2002 his research focus shifted from coagulation-inflammation research in sepsis models, to the broader field of cardiovascular (CV) disease (atherothrombosis and 'thrombo-inflammation'). A specific focus of current research is the pleiotropic actions of coagulation proteases in atherosclerosis, atherothrombosis and ischemia reperfusion injury. Clinical research is aimed at chronic thrombotic disease including peripheral artery disease, high risk patients with coronary disease on antithrombotic medication and, together with Dr Arina ten Cate-Hoek, on venous thrombosis and post thrombotic syndrome (PTS). He is workpackage leader in CVON consortia RACE-5 (coagulation and its impact on atrial fibrillation) and CONTRAST (acute ischemic stroke) and involved in the ITN consortia TAPAS and TICARDIO. His group has an ongoing target finding programme with Bayer (steered from CARIM by Dr Henri Spronk and Prof. Hugo ten Cate) as well as with 2M (on POC development).

Department of Biochemistry
Department of Internal Medicine
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 4.344
T: +31(0)43 388 42 62

  • 2020
    • Hardy, M., Lecompte, T., Douxfils, J., Lessire, S., Dogne, J. M., Chatelain, B., Testa, S., Gouin-Thibault, I., Gruel, Y., Medcalf, R. L., ten Cate, H., Lippi, G., & Mullier, F. (2020). Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thrombosis Journal, 18(1), [17].
    • van der Vorm, L. N., Li, L., Huskens, D., Hulstein, J. J. J., Roest, M., de Groot, P. G., ten Cate, H., de Laat, B., Remijn, J. A., & Simons, S. O. (2020). Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. Respiratory Medicine, 171, [106094].
    • Gulpen, A. J. W., van Dijk, J. K., Damen, N. L., ten Cate, H., Schalla, S., & Ten Cate-Hoek, A. J. (2020). Organisation of care for patients using direct oral anticoagulants. Netherlands Heart Journal, 28(9), 452-456.
    • Kremers, B., Wubbeke, L., Mees, B., ten Cate, H., Spronk, H., & ten Cate-Hoek, A. (2020). Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease A Systematic Review and Meta-Analysis. Arteriosclerosis Thrombosis and Vascular Biology, 40(9), 2018-2032.
    • van Paridon, P. C. S., Panova-Noeva, M., van Oerle, R., Schultz, A., Hermanns, I. M., Prochaska, J. H., Arnold, N., Binder, H., Schmidtmann, I., Beutel, M. E., Pfeiffer, N., Münzel, T., Lackner, K. J., Ten Cate, H., Wild, P. S., & Spronk, H. M. H. (2020). Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. Haematologica-the Hematology Journal, 105(9), 2327-2334.
    • Veninga, A., De Simone, I., Heemskerk, J. W. M., Ten Cate, H., & van der Meijden, P. E. J. (2020). Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica-the Hematology Journal, 105(8), 2020-2031.
    • Heuberger, J. A. A. C., Posthuma, J. J., Ziagkos, D., Rotmans, J., Daniels, J. M. A., Gal, P., Stuurman, F. E., Spronk, H. M. H., Cate, H. T., Burggraaf, J., Moerland, M., & Cohen, A. F. (2020). Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes. European Journal of Applied Physiology, 120(8), 1893-1904.
    • Notten, P., Arnoldussen, C. W. K. P., Brans, R., de Smet, A. A. E. A., Tick, L. W., van de Poel, M. H. W., Wikkeling, O. R. M., Vleming, L-J., Koster, A., Jie, K-S. G., Jacobs, E. M. G., Ebben, H. P., Planken, N., ten Cate, H., Wittens, C. H. A., & ten Cate-Hoek, A. J. (2020). Association of Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis with Postthrombotic Syndrome: A Post Hoc Analysis of the CAVA Trial. Thrombosis and Haemostasis, 120(08), 1188-1199.
    • Chu, G., Seelig, J., Trinks-Roerdink, E. M., van Alem, A. P., Alings, M., van den Bemt, B., Boersma, L. V. A., Brouwer, M. A., Cannegieter, S. C., ten Cate, H., Kirchhof, C. J. H. J., Crijns, H. J. G. M., van Dijk, E. J., Elvan, A., van Gelder, I. C., de Groot, J. R., den Hartog, F. R., de Jong, J. S. S. G., de Jong, S., ... Huisman, M. (2020). Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. BMJ Open, 10(8), [036220].
    • Brouns, S. H., Bruggemann, R., Linkens, A. E. M. J. H., Magdelijns, F. J., Joosten, H., Heijnen, R., ten Cate-Hoek, A. J., Schols, J. M. G. A., ten Cate, H., & Spaetgens, B. (2020). Mortality and the Use of Antithrombotic Therapies Among Nursing Home Residents withCOVID-19. Journal of the American Geriatrics Society, 68(8), 1647-1652.
    • Leader, A., ten Cate, V., ten Cate-Hoek, A. J., Beckers, E. A. M., Spectre, G., Giaccherini, C., Gurevich-Shapiro, A., Krashin, E., Raanani, P., Schouten, H. C., Falanga, A., & ten Cate, H. (2020). Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. European journal of internal medicine, 77, 86-96.
    • Jiritano, F., Serraino, G. F., ten Cate, H., Fina, D., Matteucci, M., Mastroroberto, P., & Lorusso, R. (2020). Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis. Intensive Care Medicine, 46(6), 1154-1169.
    • Visser, M., Heitmeier, S., ten Cate, H., & Spronk, H. M. H. (2020). Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis. Thrombosis and Haemostasis, 120(6), 883-893.
    • Ordieres-Ortega, L., Demelo-Rodriguez, P., Galeano-Valle, F., Kremers, B. M. M., ten Cate-Hoek, A. J., & ten Cate, H. (2020). Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review. Thrombosis Research, 189, 5-12.
    • ten Cate, H. (2020). Thrombosis management in times of COVID-19 epidemy; a Dutch perspective. Thrombosis Journal, 18(7), [7].
    • Seelig, J., Verheugt, F. W. A., Hemels, M. E. W., Illingworth, L., Lucassen, A., Adriaansen, H., Bongaerts, M. C. M., Pieterse, M., Herrman, J. P. R., Hoogslag, P., Hermans, W., Groenemeijer, B. E., Boersma, L. V. A., Pieper, K., ten Cate, H., & GARFIELD-AF Investigators (2020). Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry. Thrombosis Journal, 18(5), [5].
    • Panova-Noeva, M., van der Meijden, P. E. J., & ten Cate, H. (2020). Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets. Journal of Clinical Medicine, 9(1), [92].
    • Visser, M., van Oerle, R., ten Cate, H., Laux, V., Mackman, N., Heitmeier, S., & Spronk, H. M. H. (2020). Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX. Arteriosclerosis Thrombosis and Vascular Biology, 40(1), 103-111.
    • Notten, P., ten Cate-Hoek, A. J., Arnoldussen, C. W. K. P., Strijkers, R. H. W., de Smet, A. A. E. A., Tick, L. W., van de Poel, M. H. W., Wikkeling, O. R. M., Vleming, L-J., Koster, A., Jie, K-S. G., Jacobs, E. M. G., Ebben, H. P., Coppens, M., Toonder, I., ten Cate, H., & Wittens, C. H. A. (2020). Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. The Lancet Haematology , 7(1), E40-E49.
  • 2019
    • Panova-Noeva, M., Wagner, B., Nagler, M., Arnold, N., Prochaska, J. H., Eckerle, S., Spronk, H. M., Merzenich, H., Wingerter, A., Schneider, A., Danckwardt, S., ten Cate, H., Faber, J., & Wild, P. S. (2019). Relation between platelet coagulant and vascular function, sex-specific analysis in adult survivors of childhood cancer compared to a population-based sample. Scientific Reports, 9, [20090].
    • Jiritano, F., Santarpino, G., Serraino, G. F., Ten Cate, H., Matteucci, M., Fina, D., Mastroroberto, P., & Lorusso, R. (2019). Peri-procedural thrombocytopenia after aortic bioprosthesis implant: A systematic review and meta-analysis comparison among conventional, stentless, rapid-deployment, and transcatheter valves. International Journal of Cardiology, 296, 43-50.
    • Geersing, G-J., Greving, J. P., Folkeringa, R., Hemels, M. E. W., Ten Cate, H., & Huisman, M. V. (2019). Oerwoud van antitrombotica: een overzicht van recente literatuur. Nederlands Tijdschrift voor Geneeskunde, 163, 1-7. [D4265].
    • ten Cate, V., Nagler, M., Panova-Noeva, M., Eggebrecht, L., Arnold, N., Lamparter, H., Hermanns, M. I., ten Cate, H., Prins, M. H., Espinola-Klein, C., Muenzel, T., Lackner, K. J., Wild, P. S., & Prochaska, J. H. (2019). The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism. Haematologica-the Hematology Journal, 104(9), [424].
    • Petersohn, S., Ramaekers, B. L. T., Olie, R. H., ten Cate-Hoek, A. J., Daemen, J-W. H. C., ten Cate, H., & Joore, M. A. (2019). Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments. Quality of Life Research, 28(8), 2257-2279.
    • Eggebrecht, L., Prochaska, J. H., Troebs, S-O., Schwuchow-Thonke, S., Goebel, S., Diestelmeier, S., Schulz, A., Arnold, N., Panova-Noeva, M., Koeck, T., Rapp, S., Gori, T., Lackner, K. J., ten Cate, H., Muenzel, T., & Wild, P. S. (2019). Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism. Clinical research in cardiology, 108(7), 787-796.
    • Olie, R. H., van der Meijden, P. E. J., Spronk, H. M. H., van Oerle, R., Barvik, S., Bonarjee, V. V. S., Ten Cate, H., & Nilsen, D. W. T. (2019). Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease. TH open : companion journal to thrombosis and haemostasis, 3(3), e259-e262.
    • Govers-Riemslag, J. W. P., Konings, J., Cosemans, J. M. E. M., van Geffen, J. P., de Laat, B., Heemskerk, J. W. M., Dargaud, Y., & Ten Cate, H. (2019). Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis. TH open : companion journal to thrombosis and haemostasis, 3(3), e273-e285.
    • Gulpen, A. J. W., ten Cate, H., Henskens, Y. M. C., van Oerle, R., Wetzels, R., Schalla, S., Crijns, H. J., & ten Cate-Hoek, A. J. (2019). The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study. PLOS ONE, 14(6), [0217302].
    • Jooss, N. J., De Simone, I., Provenzale, I., Fernández, D. I., Brouns, S. L. N., Farndale, R. W., Henskens, Y. M. C., Kuijpers, M. J. E., Ten Cate, H., van der Meijden, P. E. J., Cavill, R., & Heemskerk, J. W. M. (2019). Role of Platelet Glycoprotein VI and Tyrosine Kinase Syk in Thrombus Formation on Collagen-Like Surfaces. International journal of molecular sciences, 20(11), [2788].
    • ten Cate, H., Kontny, F., & Nilsen, D. W. (2019). Editorial: Novel and potential markers for prediction of outcome in patients with acute and chronic coronary heart disease. Frontiers in cardiovascular medicine, 6, 1-3. [66].
    • Gurbel, P. A., Fox, K. A. A., Tantry, U. S., ten Cate, H., & Weitz, J. (2019). Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease Focus on the COMPASS Trial. Circulation, 139(18), 2170-2185.
    • Kremers, B. M. M., Birocchi, S., van Oerle, R., Zeerleder, S., Spronk, H. M. H., Mees, B. M. E., Luken, B. M., ten Cate, H., & ten Cate-Hoek, A. J. (2019). Searching for a Common Thrombo-Inflammatory Basis in Patients With Deep Vein Thrombosis or Peripheral Artery Disease. Frontiers in cardiovascular medicine, 6, 1-11. [33].
    • Panova-Noeva, M., Neu, M. A., Eckerle, S., Spix, C., Schneider, A., Schmidtmann, I., Spronk, H. M., Pfeiffer, N., Beutel, M., Lackner, K. J., Muenzel, T., ten Cate, H., Merzenich, H., Faber, J., & Wild, P. S. (2019). Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer. Clinical research in cardiology, 108(4), 438-447.
    • Posthuma, J. J., Posma, J. J. N., Schep, G., Bender, M. M. H., van Oerle, R., van der Wal, A. C., Ten Cate, H., & Spronk, H. M. H. (2019). Protease-activated receptors are potential regulators in the development of arterial endofibrosis in high-performance athletes. Journal of Vascular Surgery, 69(4), 1243-1250.
    • Posthuma, J. J., Posma, J. J. N., van Oerle, R., Leenders, P., van Gorp, R. H., Jaminon, A. M. G., Mackman, N., Heitmeier, S., Schurgers, L. J., ten Cate, H., & Spronk, H. M. H. (2019). Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice. Scientific Reports, 9, [3909].
    • Donkel, S. J., Benaddi, B., Dippel, D. W. J., ten Cate, H., & de Maat, M. P. M. (2019). Prognostic Hemostasis Biomarkers in Acute Ischemic Stroke: A Systematic Review. Arteriosclerosis Thrombosis and Vascular Biology, 39(3), 360-372.
    • Vries, M. J. A., Macrae, F., Nelemans, P. J., Kuiper, G. J. A. J. M., Wetzels, R. J. H., Bowman, P., Verhezen, P. W. M., ten Cate, H., Ariens, R. A. S., & Henskens, Y. M. C. (2019). Assessment and determinants of whole blood and plasma fibrinolysis in patients with mild bleeding symptoms. Thrombosis Research, 174, 88-94.
    • Kuiper, G. J. A. J. M., van Egmond, L. T., Henskens, Y. M. C., Roekaerts, P. M., Maessen, J. G., ten Cate, H., Buhre, W. F., & Lance, M. D. (2019). Shifts of Transfusion Demand in Cardiac Surgery After Implementation of Rotational Thromboelastometry-Guided Transfusion Protocols: Analysis of the HEROES-CS (HEmostasis Registry of patiEntS in Cardiac Surgery) Observational, Prospective Open Cohort Database. Journal of Cardiothoracic and Vascular Anesthesia, 33(2), 307-317.
    • Grottke, O., van Ryn, J., Zentai, C., Gan, G., Honickel, M., Rossaint, R., Ten Cate, H., & Spronk, H. M. H. (2019). Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution. PLOS ONE, 14(1), e0209350. [0209350].
    • Moenen, F. C. J., Vries, M. J. A., Nelemans, P. J., van Rooy, K. J. M., Vranken, J. R. R. A., Verhezen, P. W. M., Wetzels, R. J. H., ten Cate, H., Schouten, H. C., Beckers, E. A. M., & Henskens, Y. M. C. (2019). Screening for platelet function disorders with Multiplate and platelet function analyzer. Platelets, 30(1), 81-87.
    • Leader, A., Ten Cate, V., Ten Cate-Hoek, A. J., Spectre, G., Beckers, E. A. M., Raanani, P., Giaccherini, C., Pereg, D., Schouten, H. C., Falanga, A., & Ten Cate, H. (2019). Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment. Thrombosis and Haemostasis, 119(1), 163-174.
    • Ratzon, R., Tamir, S., Friehmann, T., Livneh, N., Dudnik, E., Rozental, A., Hamburger-Avnery, O., Pereg, D., Derazne, E., Brenner, B., Raanani, P., ten Cate, H., Spectre, G., & Leader, A. (2019). Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. Journal of Thrombosis and Thrombolysis, 47(1), 121-128.
    • Seelig, J., Pisters, R., Hemels, M. E., Huisman, M. V., ten Cate, H., & Alings, M. (2019). When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics. Vascular health and risk management, 15, 399-408.
  • 2018
    • Leader, A., ten Cate, H., Spectre, G., Beckers, E. A. M., & Falanga, A. (2018). Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps. Critical Reviews in Oncology/Hematology, 132, 76-88.
    • Prochaska, J. H., Goebel, S., Nagler, M., Knoepfler, T., Eggebrecht, L., Lamparter, H., Panova-Noeva, M., Keller, K., Coldewey, M., Bickel, C., Lauterbach, M., Hardt, R., Espinola-Klein, C., ten Cate, H., Rostock, T., Muenzel, T., & Wild, P. S. (2018). Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure. Clinical research in cardiology, 107(12), 1170-1179.
    • Amin, E. E., Bistervels, I. M., Meijer, K., Tick, L. W., Middeldorp, S., Mostard, G., van de Poel, M., Serne, E. H., Otten, H. M., Klappe, E. M., Joore, M. A., ten Cate, H., ten Wolde, M., & ten Cate-Hoek, A. J. (2018). Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood, 132(21), 2298-2304.
    • Favresse, J., Lippi, G., Roy, P-M., Chatelain, B., Jacqmin, H., ten Cate, H., & Mullier, F. (2018). D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications . Critical Reviews in Clinical Laboratory Sciences, 55(8), 548-577.
    • Amin, E. E., ten Cate-Hoek, A. J., Bouman, A. C., Meijer, K., Tick, L., Middeldorp, S., Mostard, G., ten Wolde, M., van den Heiligenberg, S., van Wissen, S., van de Poet, M., Villalta, S., Serne, E., Otten, H. M., Klappe, E., Prandoni, P., Prins, M. H., ten Cate, H., & Joore, M. A. (2018). Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. The Lancet Haematology , 5(11), E512-E519.
    • Goebel, S., Prochaska, J. H., Eggebrecht, L., Schmitz, R., Juenger, C., Lamparter, H., Nagler, M., Keller, K., Coldewey, M., Troebs, S-O., Diestelmeier, S., Schwuchow-Thonke, S., Bickel, C., Lauterbach, M., Lackner, K. J., ten Cate, H., Muenzel, T., Hardt, R., & Wild, P. S. (2018). Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study. Thrombosis and Haemostasis, 118(11), 1930-1939.
    • ten Cate, H., Lensing, A. W. A., Weitz, J. I., Middeldorp, S., Beyer-Westendorf, J., Kubitza, D., Brighton, T., Raskob, G. E., Mismetti, P., Prandoni, P., Gebel, M., & Prins, M. H. (2018). The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thrombosis Research, 170, 75-83.